For Respiratory Clinicians

Your clinic can keep watch while patients are at home.

RespiroScreen continuously monitors COPD and asthma patients between appointments. Graded alerts flag pattern changes before hospital admission.

Request a Free Pilot

Respiratory clinician reviewing patient monitoring data at a workstation in a warm consulting room

Clinical Workflow

How RespiroScreen works in your practice

No additional hardware or prescribing changes are required. RespiroScreen adds acoustic monitoring for the COPD patients already under your care.

Downloads RespiroScreen app

Invite a patient by email or NHS email. They download the app, complete 5-minute onboarding, and begin the baseline period. No hardware needs shipping or collection.

The app records airway acoustics

Each morning, patient completes a 90-second breath check. During the first two weeks, AI establishes a personal acoustic baseline. Real-time monitoring and alerting start on day 15.

AI detects unusual pattern

If the model finds a change above the WATCH threshold, it issues an alert and identifies the acoustic feature involved. This informs clinical judgement without replacing it.

Clinician sees priority alerts in dashboard

CRITICAL patients appear first. Review the acoustic trend, record a clinical note, then arrange a telephone review or prescription adjustment directly from the dashboard.

Alert System

Three severity alert tiers

Alerts are prioritised rather than sent as undifferentiated noise. CRITICAL notifications arrive by email and in the dashboard, while NORMAL patients stay visible without interrupting routine work.

Patient J. Morris CRITICAL

Spirometry decline across 3 readings. RespiroScore: 82, rising.

2h ago

Patient A. Patel WATCH

Nocturnal wheeze found, with no prior event in this patient's history.

Yesterday

Patient R. Hollis NORMAL

No abnormality found. Acoustic pattern within personal baseline range.

3 days ago

Early Access Evidence

Evidence from our 12-week NHS-affiliated pilot

The figures come from an early access programme at an NHS-affiliated teaching hospital. Results remain preliminary and are pending peer review.

~87%

Exacerbation detection rate

4.8 days

Mean early-warning lead time

11%

False positive rate, early-access cohort

12-week NHS-affiliated early access programme, n=47 COPD patients, Stage II-IV. Peer review pending.

View Full Evidence Summary

90-Day Free Pilot

Pilot RespiroScreen with complex COPD patients

Free for 90 days, up to 10 patients. No EHR integration is needed to start. We provide onboarding and direct app support for patients.

Request a Free Pilot View Pricing